Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first erythroid maturation agent for first-line treatment of patients with ...
In this study, we demonstrated that insufficient erythropoiesis in an immunocompetent acute myeloid leukemia (AML) murine model was due to reduced proliferation of megakaryocyte erythroid ...
Jan Frayne’s group in the School of Biochemistry renowned for the creation of the Bristol Erythroid Line – Adult (BEL-A ... to study erythropoiesis in disease states and for use in the development of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback